ACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024. In the quarter to June 2026, revenue grew 16.4%, EPS grew 12.5% and free cash flow grew 50.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow ACAD
ACADIA Pharmaceuticals Inc. (ACAD) EV/Sales
As of 16 October 2026, ACADIA Pharmaceuticals Inc. (ACAD) trades at a EV/Sales of 2.0×. Over the past ten years it has ranged from 1.7× (April 2025) to 70,999× (July 2015); the current reading is higher than 1% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.4× | 43.85% |
| FY2024 | 2.4× | (62.46%) |
| FY2023 | 6.4× | 47.94% |
| FY2022 | 4.3× | (35.52%) |
| FY2021 | 6.7× | (62.17%) |
| FY2020 | 17.6× | 6.63% |
| FY2019 | 16.5× | 134.91% |
| FY2018 | 7.0× | (74.09%) |
| FY2017 | 27.1× | (83.23%) |
| FY2016 | 162× | (99.71%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.0× | 10.59% |
| Mar 2026 | 2.7× | (21.67%) |
| Dec 2025 | 3.4× | 30.39% |
| Sep 2025 | 2.6× | (6.17%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | n/m |
| VKTX Viking Therapeutics, Inc. compare | n/m |
| ACAD ACADIA Pharmaceuticals Inc. | 2.0× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 4.3× |
| ARQT Arcutis Biotherapeutics, Inc. compare | 7.8× |
| IDYA IDEAYA Biosciences, Inc. compare | 9.4× |
| TNGX Tango Therapeutics, Inc. compare | 36.7× |
| XENE Xenon Pharmaceuticals Inc. compare | 144× |
| RLAY Relay Therapeutics, Inc. compare | 217× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)